1. Exploring the ubiquitin proteasomal system in Toxoplasma gondii
- Abstract
The phylum Apicomplexa comprises a group of unicellular eukaryotic organisms including Plasmodium spp., Toxoplasma gondii and Cryptosporidium spp. Infection with Toxoplasma gondii causes severe congenital birth defects and disease in immunocompromised individuals and persists for life. Efforts to develop effective vaccines have been unsuccessful and emergence of drug resistance has reduced the utility of current antiparasitic compounds, highlighting the need for new therapeutics. My PhD focussed on two areas: Firstly, understanding degradative ubiquitination in apicomplexan parasites as a step towards developing first in class anti-apicomplexan PROTACS. PROTACS are heterobifunctional molecules which on one end bind an E3 ubiquitin ligase and force it to bind with a neo-substrate which is then degraded via the proteasome. This technique has shown great promise in developing new therapeutic approaches to treat disease like cancer but has never been tested against any apicomplexan parasite. The absence of conventionally used E3 ligases for PROTAC development became a challenge which I decided to overcome during my thesis. I developed a new system to screen for degradative parasite E3 ubiquitin ligases that can be used to enhance current therapies. The second part of my PhD focused on the role of ubiquitination during differentiation of Toxoplasma gondii into latent stages. We performed a whole genome CRISPR screen to identify genes required for differentiation into latent forms. The screen identified several genes involved in protein ubiquitination. These encompassed a complete multi protein E3 ubiquitin ligase complex that regulates differentiation from acute to latent forms and was the orthologue of the GID/CTLH E3 ligase complex which has been characterised in yeast and humans. Genetic removal of this complex resulted in markedly reduced cyst formation in vitro even in conditions favouring differentiation and reduced burden in the brain in vivo. Furthermore, we have
- Published
- 2022